Traverse: A Phase 2, Open-Label, Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment-Naive Mantle Cell Lymphoma

被引：2
|
作者：
Hawkes, Eliza A. [1 ]
Fletcher, Rachel [2 ]
Wood, Andrew [2 ]
Meyer, Stefanie [3 ]
Rule, Simon [4 ]
Zhang, Jingyang [5 ]
Wang, Michael L. [6 ]
机构：
[1] Austin Hlth, Olivia Newton John Canc Res & Wellness Ctr, Heidelberg, Vic, Australia
[2] AstraZeneca, Cambridge, England
[3] AstraZeneca, Waltham, MA USA
[4] AstraZeneca, Mississauga, ON, Canada
[5] AstraZeneca, San Francisco, CA USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-174718
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Safety and Efficacy of Acalabrutinib Plus Venetoclax and Rituximab in Patients With Treatment-Naive Mantle Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 6 - 7
  • [2] ACRUE: A Phase 2, Open-Label Study of Acalabrutinib in Combination With Rituximab in Elderly and/or Frail Patients With Treatment-Naive Diffuse Large B- Cell Lymphoma
    Perini, Guilherme F.
    Graff, Tara
    Roos, Jack
    Hermann, Richard
    Lovenklev, Magnus
    Shaw, Bob
    Budde, Lihua E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S462 - S462
  • [3] Acrue: A Phase 2, Open-Label Study of Acalabrutinib in Combination with Rituximab in Elderly and/or Frail Patients with Treatment-Naive Diffuse Large B-Cell Lymphoma
    Perini, Guilherme F.
    Graff, Tara
    Roos, Jack
    Hermann, Richard
    Lovenklev, Magnus
    Shaw, Bob
    Budde, L. Elizabeth
    BLOOD, 2023, 142
  • [4] Safety and Efficacy of Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naive (TN) Mantle Cell Lymphoma (MCL)
    Wang, Michael
    Robak, Tadeusz
    Maddocks, Kami J.
    Phillips, Tycel
    Smith, Stephen D.
    Gallinson, David
    Calvo, Roser
    Wun, Chuan-Chuan
    Munugalavadla, Veerendra
    Jurczak, Wojciech
    BLOOD, 2021, 138
  • [5] Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis
    Wang, Michael
    Robak, Tadeusz
    Maddocks, Kami J.
    Phillips, Tycel
    Smith, Stephen D.
    Gallinson, David
    Calvo, Roser
    Wun, Chuan-Chuan
    Munugalavadla, Veerendra
    Jurczak, Wojciech
    BLOOD ADVANCES, 2024, 8 (17) : 4539 - 4548
  • [6] Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study
    Strati, Paolo
    Champion, Rebecca
    Coleman, Morton
    Smith, Sonali M.
    Venugopal, Parameswaran
    Martin, Peter
    Wood, Andrew
    Miller, Kara
    Christian, Beth
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (06) : 2248 - 2253
  • [7] Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naive (TN) Mantle Cell Lymphoma (MCL): 2Year Safety and Efficacy Analysis
    Wang, Michael
    Robak, Tadeusz
    Maddocks, Kami J.
    Phillips, Tycel
    Smith, Stephen D.
    Gallinson, David
    Calvo, Roser
    Wun, Chuan-Chuan
    Munugalavadla, Veerendra
    Jurczak, Wojciech
    BLOOD, 2022, 140 : 6477 - 6479
  • [8] Acalabrutinib in Combination With Venetoclax and Obinutuzumab or Rituximab in Patients With Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 9 - 10
  • [9] Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia
    Woyach, Jennifer A.
    Blachly, James S.
    Rogers, Kerry A.
    Bhat, Seema A.
    Grever, Michael R.
    Kittai, Adam S.
    Jianfar, Mojgan
    Lozanski, Gerard
    Weiss, David M.
    Andersen, Barbara L.
    Patel, Priti
    Munugalavadla, Veerendra
    Butturini, Anna
    Xu, Yan
    Wang, Min Hui
    Byrd, John C.
    BLOOD, 2020, 136
  • [10] Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naive Mantle Cell Lymphoma
    Ruan, Jia
    Leonard, John P.
    Chen, Gui Zhen
    Chen, Zhengming
    Allan, John N.
    Rutherford, Sarah C.
    Hobbie, Brittany
    Greig, Katie
    Rodriguez, Amelyn
    Tam, Wayne
    Bond, David A.
    Shah, Bijal D.
    Maddocks, Kami J.
    Binder, Bhavneet
    Inghirami, Giorgio
    Elemento, Olivier
    Chen-Kiang, Selina
    Martin, Peter
    BLOOD, 2022, 140
12345